Uncomplicated urinary tract infections: In focus: Pivmecillinam and nitroxoline in the antibiotic treatment

被引：2
作者：
Hof H. [1 ]
机构：
[1] MVZ Labor Limbach und Kollegen, Im Breitspiel 16, Heidelberg
来源：
Der Gynäkologe | 2018年 / 51卷 / 7期
关键词：
Antibiotic resistance; Escherichia coli; Microbial sensitivity tests; Nitroxoline; Pivmecillinam;
D O I：
10.1007/s00129-018-4263-z
中图分类号：
学科分类号：
摘要：
The new S3 guidelines on urinary tract infections no longer recommend quinolones as first-line treatment. In addition to fosfomycin, nitrofurantoin and pivmecillinam, which is now available on the market in Germany, nitroxoline is now also placed as a primary medication for the calculated treatment of uncomplicated urinary tract infections. Nitroxoline is also approved for prophylaxis of recurrent urinary tract infections. The importance of the diverse antibiotics in comparison to pivmecillinam and nitroxoline is explained. The possibilities for prevention are also briefly presented. © 2018, Springer Verlag. All rights reserved.
引用
收藏
页码：581 / 589
页数：8
相关论文
共 31 条
[1]  
Ingersoll M.A., Albert M.L., From infection to immunotherapy: host immune responses to bacteria at the bladder mucosa, Mucosal Immunol, 6, pp. 1041-1053, (2013)
[2]  
Hof H., Harnwegsinfektionen – Teil 1: Pathogenese, Prakt Gynecol, 20, pp. 358-365, (2015)
[3]  
Dobrindt U., Virulenzfaktoren uropathogener Erreger, Urologe, 49, pp. 598-605, (2010)
[4]  
Alteri C.J., Mobley H.L., Metabolism and fitness of urinary tract pathogens, Microbiol Spectr, (2015)
[5]  
Hooton T.M., Roberts P.L., Cox M.E., Stapleton A.E., Voided midstream urine culture and acute cystitis in premonopausal women, N. Engl. J. Med., 369, pp. 18883-18891, (2013)
[6]  
Bodman K.F., Therapiemanagement nosokomialer Infektionen, (2012)
[7]  
Wagenlehner F., Schiemann G., Interdisziplinäre S3 Leitlinie. Epidemiologie, Diagnostik, Therapie, Prävention und Management unkomplizierter, bakterieller, ambulant erworbener Harnwegsinfektionen bei erwachsenen Patienten, (2017)
[8]  
Parsons R.L., Hossack G.A., Paddock G.M., Pharmacokinetics of pivmecillinam, Br J Clin Pharmacol, 4, pp. 267-273, (1977)
[9]  
Graninger W., Pivmecillinam—therapy of choice for lower urinary tract infection, Int J Antimicrob Agents, 22, pp. 73-78, (2003)
[10]  
Kresken M., Korber-Irrgang B., Naber K.G., In-vitro Wirksamkeit von Mecillinam gegen Urinisolate von Escherichia coli von Patienten im niedergelassenen Versorgungsbereich in Deutschland, Aktuelle Urol, 48, pp. 243-247, (2017)
1234